Myocardial Infarction – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Myocardial Infarction – Pipeline Review, H1 2017’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction

– The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects

– The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amarantus Bioscience Holdings Inc

AstraZeneca Plc

Athersys Inc

Bayer AG

Bharat Biotech International Ltd

BioCardia Inc

Biscayne Pharmaceuticals Inc

Capricor Therapeutics Inc

CellProthera

Chrysalis BioTherapeutics Inc

Compugen Ltd

Cynata Therapeutics Limited

Diffusion Pharmaceuticals Inc

FibroGen Inc

Hemostemix Ltd

Human Stem Cells Institute

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Inotrem SA

Juventas Therapeutics Inc

Laboratoires Pierre Fabre SA

Lee's Pharmaceutical Holdings Ltd

LG Chem, Ltd.

Medestea Research & Production SpA

Mesoblast Ltd

Moderna Therapeutics Inc

Navya Biologicals Pvt Ltd

New World Laboratories Inc

Novartis AG

NuvOx Pharma LLC

Omeros Corp

Opsona Therapeutics Ltd

Otsuka Holdings Co Ltd

Pharmahungary Group

Primary Peptides Inc

Quark Pharmaceuticals Inc

Recardio GmbH

RegeneRx Biopharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Rubicon Biotechnology Inc

Serodus ASA

Silver Creek Pharmaceuticals Inc

Stemedica Cell Technologies Inc

TaiGen Biotechnology Co Ltd

Targazyme Inc

Tasly Pharmaceutical Group Co Ltd

The International Biotechnology Center (IBC) Generium

TiGenix NV

Vicore Pharma AB

XBiotech Inc

Yuyu Pharma Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Myocardial Infarction Overview 6

Myocardial Infarction Therapeutics Development 7

Myocardial Infarction Therapeutics Assessment 22

Myocardial Infarction Companies Involved in Therapeutics Development 34

Myocardial Infarction Drug Profiles 60

Myocardial Infarction Dormant Projects 275

Myocardial Infarction Discontinued Products 281

Myocardial Infarction Product Development Milestones 282

Appendix 295

List of Tables

List of Tables

Number of Products under Development for Myocardial Infarction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Myocardial Infarction Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Myocardial Infarction Pipeline by AstraZeneca Plc, H1 2017

Myocardial Infarction Pipeline by Athersys Inc, H1 2017

Myocardial Infarction Pipeline by Bayer AG, H1 2017

Myocardial Infarction Pipeline by Bharat Biotech International Ltd, H1 2017

Myocardial Infarction Pipeline by BioCardia Inc, H1 2017

Myocardial Infarction Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

Myocardial Infarction Pipeline by Capricor Therapeutics Inc, H1 2017

Myocardial Infarction Pipeline by CellProthera, H1 2017

Myocardial Infarction Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Myocardial Infarction Pipeline by Compugen Ltd, H1 2017

Myocardial Infarction Pipeline by Cynata Therapeutics Limited, H1 2017

Myocardial Infarction Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Myocardial Infarction Pipeline by FibroGen Inc, H1 2017

Myocardial Infarction Pipeline by Hemostemix Ltd, H1 2017

Myocardial Infarction Pipeline by Human Stem Cells Institute, H1 2017

Myocardial Infarction Pipeline by HUYA Bioscience International LLC, H1 2017

Myocardial Infarction Pipeline by InCarda Therapeutics Inc, H1 2017

Myocardial Infarction Pipeline by Inotrem SA, H1 2017

Myocardial Infarction Pipeline by Juventas Therapeutics Inc, H1 2017

Myocardial Infarction Pipeline by Laboratoires Pierre Fabre SA, H1 2017

Myocardial Infarction Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Myocardial Infarction Pipeline by LG Chem, Ltd., H1 2017

Myocardial Infarction Pipeline by Medestea Research & Production SpA, H1 2017

Myocardial Infarction Pipeline by Mesoblast Ltd, H1 2017

Myocardial Infarction Pipeline by Moderna Therapeutics Inc, H1 2017

Myocardial Infarction Pipeline by Navya Biologicals Pvt Ltd, H1 2017

Myocardial Infarction Pipeline by New World Laboratories Inc, H1 2017

Myocardial Infarction Pipeline by Novartis AG, H1 2017

Myocardial Infarction Pipeline by NuvOx Pharma LLC, H1 2017

Myocardial Infarction Pipeline by Omeros Corp, H1 2017

Myocardial Infarction Pipeline by Opsona Therapeutics Ltd, H1 2017

Myocardial Infarction Pipeline by Otsuka Holdings Co Ltd, H1 2017

Myocardial Infarction Pipeline by Pharmahungary Group, H1 2017

Myocardial Infarction Pipeline by Primary Peptides Inc, H1 2017

Myocardial Infarction Pipeline by Quark Pharmaceuticals Inc, H1 2017

Myocardial Infarction Pipeline by Recardio GmbH, H1 2017

Myocardial Infarction Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Myocardial Infarction Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Myocardial Infarction Pipeline by Rubicon Biotechnology Inc, H1 2017

Myocardial Infarction Pipeline by Serodus ASA, H1 2017

Myocardial Infarction Pipeline by Silver Creek Pharmaceuticals Inc, H1 2017

Myocardial Infarction Pipeline by Stemedica Cell Technologies Inc, H1 2017

Myocardial Infarction Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Myocardial Infarction Pipeline by Targazyme Inc, H1 2017

Myocardial Infarction Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Myocardial Infarction Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017

Myocardial Infarction Pipeline by TiGenix NV, H1 2017

Myocardial Infarction Pipeline by Vicore Pharma AB, H1 2017

Myocardial Infarction Pipeline by XBiotech Inc, H1 2017

Myocardial Infarction Pipeline by Yuyu Pharma Inc, H1 2017

Myocardial Infarction Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Myocardial Infarction Dormant Projects, H1 2017

Myocardial Infarction Dormant Projects, H1 2017 (Contd..1), H1 2017

Myocardial Infarction Dormant Projects, H1 2017 (Contd..2), H1 2017

Myocardial Infarction Dormant Projects, H1 2017 (Contd..3), H1 2017

Myocardial Infarction Dormant Projects, H1 2017 (Contd..4), H1 2017

Myocardial Infarction Dormant Projects, H1 2017 (Contd..5), H1 2017

Myocardial Infarction Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Myocardial Infarction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports